Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Price Expected to Rise, HC Wainwright Analyst Says

Mirum Pharmaceuticals (NASDAQ:MIRM) had its price objective raised by stock analysts at HC Wainwright from $195.00 to $200.00 in a research report issued on Monday, Marketbeat Ratings reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price objective suggests a potential upside of 151.19% from the stock’s current price. HC Wainwright also issued estimates for Mirum Pharmaceuticals’ Q3 2027 earnings at $0.27 EPS.

MIRM has been the topic of a number of other reports. Wall Street Zen lowered shares of Mirum Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, September 6th. Citizens Jmp restated a “market outperform” rating and issued a $137.00 price target on shares of Mirum Pharmaceuticals in a research report on Thursday, August 27th. TD Cowen reaffirmed a “buy” rating on shares of Mirum Pharmaceuticals in a report on Monday. Robert W. Baird lifted their price objective on Mirum Pharmaceuticals from $123.00 to $130.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 29th. Finally, Citigroup reiterated a “buy” rating and set a $160.00 price objective (up from $145.00) on shares of Mirum Pharmaceuticals in a research report on Monday, September 28th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $146.62.

Mirum Pharmaceuticals Price Performance

NASDAQ:MIRM opened at $79.62 on Monday. The company’s 50-day moving average price is $94.21 and its 200-day moving average price is $100.88. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.86 and a quick ratio of 2.74. Mirum Pharmaceuticals has a twelve month low of $63.23 and a twelve month high of $130.00.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.32). Mirum Pharmaceuticals had a negative net margin of 139.18% and a negative return on equity of 36.28%. The business had revenue of $176.24 million for the quarter, compared to analysts’ expectations of $166.33 million. During the same period in the prior year, the company posted ($0.12) EPS. The firm’s revenue was up 37.9% on a year-over-year basis. On average, research analysts expect that Mirum Pharmaceuticals will post -1.31 earnings per share for the current year.

Insider Buying and Selling

In other Mirum Pharmaceuticals news, CEO Christopher Peetz sold 30,000 shares of the firm’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $98.68, for a total transaction of $2,960,400.00. Following the completion of the sale, the chief executive officer owned 194,440 shares of the company’s stock, valued at $19,187,339.20. This trade represents a 13.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Jolanda Howe sold 40,000 shares of Mirum Pharmaceuticals stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $100.00, for a total value of $4,000,000.00. Following the completion of the sale, the senior vice president owned 1,274 shares in the company, valued at $127,400. This represents a 96.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 98,499 shares of company stock worth $9,797,834. Company insiders own 8.32% of the company’s stock.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Several large investors have recently modified their holdings of MIRM. ABS Investment Management LLC purchased a new position in shares of Mirum Pharmaceuticals during the 2nd quarter worth $245,847,000. Integrated Wealth Concepts LLC purchased a new stake in Mirum Pharmaceuticals in the 2nd quarter valued at about $27,000. Quantbot Technologies LP purchased a new stake in Mirum Pharmaceuticals in the 2nd quarter valued at about $44,000. State of Wyoming purchased a new stake in Mirum Pharmaceuticals in the 2nd quarter valued at about $52,000. Finally, Summit Securities Group LLC purchased a new stake in Mirum Pharmaceuticals in the 1st quarter valued at about $42,000.

Key Headlines Impacting Mirum Pharmaceuticals

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: LIVMARLI met the primary endpoint in the Phase 3 EXPAND study, improving cholestatic pruritus and reducing serum bile acids in patients with ultra-rare cholestatic liver diseases. Mirum plans to submit the data to the FDA in 2027, potentially expanding LIVMARLI’s commercial opportunity. Mirum’s Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases
• Positive Sentiment: The positive Phase 3 results strengthen the outlook for LIVMARLI, Mirum’s key commercial product, and may support future revenue growth if regulators approve the expanded indication. Mirum Pharmaceuticals Reports Positive Phase 3 LIVMARLI Results
• Positive Sentiment: Citigroup raised its price target to $184 from $160 and maintained a Buy rating. HC Wainwright also lifted its target to $200 and retained its Buy rating, signaling substantial long-term upside in analysts’ models.
• Neutral Sentiment: Analyst coverage remains broadly optimistic, although the consensus still projects a full-year loss of approximately $1.31 per share, underscoring that Mirum is not yet consistently profitable.
• Negative Sentiment: HC Wainwright lowered its third-quarter 2027 earnings estimate to $0.27 per share from $0.35. The cut may be weighing on the stock because it suggests a less favorable near-term earnings trajectory despite the strong clinical update.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines for rare diseases of the liver and gastrointestinal system. The company’s work centers on conditions involving impaired bile acid transport and cholestasis, which can cause serious liver damage and debilitating symptoms such as itching.

Mirum’s primary commercial product is Livmarli (maralixibat), an oral ileal bile acid transporter inhibitor. In the United States, Livmarli is approved to treat cholestatic pruritus associated with Alagille syndrome and progressive familial intrahepatic cholestasis in eligible pediatric patients.